Pancreatic Cancer

Dear Colleagues,

Pancreatic cancer is one of the most deadly diseases and ranks third in cancer-related deaths. Patients diagnosed with Pancreatic Ductal Adenocarcinoma (PDA) have only a 5% 5-year survival rate. Currently, there are few effective therapeutic options and biomarkers available for standard patient care. In this special issue, we will focus on recent developments in pancreatic cancer, which include but are not limited to novel biomarkers, pancreatic cancer genetics and epigenetics, cancer immunology, tumor metabolism, tumor microenvironment and new therapeutic strategies, in an effort to understand mechanisms for early detection, personalized medicine, and to develop new therapies to approach this deadly disease.

Keywords

Submission Deadline: 30 September 2019

Online Submission

Manuscripts should be submitted online through Hapres Online Submission System. Please visit Guide for Authors before submitting a manuscript. Authors are encouraged to submit a paper as soon as it is ready and don’t need to wait until the deadline. Submissions will be sent to peer-review in order of arrival. Accepted papers will be published continuously in Med One and then gathered together on the special issue webpage. We welcome Research articles, Review papers, Meta-Analysis articles, and Perspectives. There are no word limits for each article type. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for approval.